Net profit rose 12.76% year-over-year to RMB 3.19 billion on revenue of RMB 20.46 billion, with strong growth in core pharmaceutical and health product segments. Cash flow and margins improved, and the company completed a major share repurchase cancellation and issued RMB 1 billion in ultra short-term bonds.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.